THALES
12.6.2019 07:02:08 CEST | Business Wire | Press release
Gemalto, a Thales company, is launching its Identity Management System (IDMS) that can help governments address the challenges posed by a world in which over one billion people have no official ID. Using the latest biometric capture and identity verification techniques, Gemalto’s solutions enable public authorities to empower citizens with a fully secured and trusted Foundational Identity. This system supports people identification and authentication so they can securely access online and offline services such as education or healthcare, and proves their right to participate in elections, apply for a passport or open a bank account. Users retain full control over their personal data, choosing how and when it is shared with service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005462/en/
UN targets universal provision of ID by 2030
The staggering number of citizens rendered invisible to public agencies by the absence of an official ID includes one out of three children worldwide. Most international financial institutions are supporting Digital ID schemes in many countries over the next ten years. These initiatives are also backed by the UN, which has itself set the target of everyone on the planet having a legal identity by 20301 .
Mobile, biometric-based registration can reach remote and isolated areas
Gemalto’s IDMS provides authorities with a fully integrated, end-to-end solution which can adapt to existing identity schemes and orchestrate its interactions. The process starts with registration of a person and capture of their biometrics, with easy-to use mobile technology ensuring coverage can reach even the most remote regions. Registration is followed by entry onto a central database or civil registry and the creation of a unique individual identifier.
Reaping the benefits of Foundational ID
This Foundational Identity can provide the basis for issuance of digital and physical ID credentials, and subsequent registration with numerous different public bodies and services. All these processes can be verified beyond doubt using the individual’s biometrics and unique identifier. Gemalto’s approach also offers citizens outstanding protection, and assurance that their data will not be used for commercial gain.
Promoting inclusion, fighting fraud
For governments, a universal ID program facilitates accurate planning of public services, and comprehensive social inclusion strategies. Robust protection against the threat of fraud is also provided, as part of the digital ID platform to further boost efficiency, convenience and adoption of eServices. The Foundational Identity also eliminates the need for individual bodies, such as those responsible for health and welfare, to continually repeat enrollment procedures.
“A unique legal ID is a basic human right that can unlock access to many more – including education, welfare and participation in the democratic process,” said Frédéric Trojani, senior vice president Identity and Biometric Solutions for Thales . “Our Identity Management System leverages unrivalled experience in delivering Digital Identity solutions that empower citizens, defend their personal data, and ensure unhindered access to the rights and services.”
Note to editors
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. Gemalto’s technologies and services authenticate people, transactions and objects, encrypt data and create value for software – enabling businesses and governments to deliver secure digital services for billions of individuals and things.
About Thales
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.
PLEASE VISIT
Thales
Group
Digital
Security
Download
HD photos
1 UN Sustainable Development Goal (SDG) 16.9
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005462/en/
Contact:
PRESS Thales, Media Relations Security Constance Arnoux +33 (0)6 44 12 16 35 constance.arnoux@thalesgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt5.10.2026 09:42:00 CEST | Press release
In a first-of-its-kind mission, TII’s probe aboard the MBR Explorer will journey past six asteroids in the main belt before landing on 269 Justitia, making it only the seventh asteroid in history to be reached on its surface by a probeDesigned, built and tested in Abu Dhabi, TII’s probe is the mission’s only deployable payload, operating fully autonomously around and on JustitiaThought to have formed in the distant Kuiper Belt in the outer Solar System, 269 Justitia may preserve clues to how water and organic material were distributed during the formation of the planetsWatch the EMA hero film here The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main
JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope5.10.2026 09:30:00 CEST | Press release
JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928207899/en/ HAXIS Low-angle Ion Milling Scanning Electron Microscope HAXIS Low-angle Ion Milling Scanning Electron Microscope Background of development As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods. JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques. HAXIS is JE
Slate Asset Management and OneIM Agree to Acquire Portfolio of Grocery-Anchored Essential Real Estate in the Greater Oslo Region Valued at Approximately €250 Million5.10.2026 08:30:00 CEST | Press release
Slate Asset Management ("Slate"), a global investor and manager focused on essential real estate and infrastructure assets, and One Investment Management (“OneIM”), a global alternative investment manager, today announced they have agreed to acquire a portfolio of eight grocery-anchored retail parks in Norway from Tellus Eiendom AS. The portfolio is located in the Greater Oslo region and is anchored by Norway's leading grocery operators and discount retailers. “We are pleased to be expanding our European Essential real estate platform with this significant acquisition,” said Brady Welch, Co-Founding Partner of Slate Asset Management. “These eight retail parks sit in dominant locations along major transport corridors around Oslo. The portfolio is anchored by Norway's strongest grocery operators and benefits from CPI-linked lease structures, designed to provide durable, inflation-protected cash flows. We look forward to applying our active management to unlock the portfolio’s full potent
Bial Showcases Parkinson’s Research at MDS 20265.10.2026 08:00:00 CEST | Press release
New data provide insights into the experiences and perceptions of people living with Parkinson’s and treatment outcomes Three posters and one oral presentation focus on the discontinued investigational compound BIA 28-6156 [INTENDED FOR MEDICAL AND TRADE MEDIA ONLY] Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), taking place in Seoul, Korea, from 4 to 8 October. Reflecting Bial’s commitment to listening to and learning directly from people living with Parkinson’s, two presentations cover research initiatives focused on understanding their experiences, perspectives, and priorities. The first is the Patient Endpoint Preference Project (PEPP), an ongoing multinational observational study that seeks to identify and prioritise the symptoms and outcomes that matter most to people living with Parkinson’s. The second is th
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press release
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
